TSX Exchange Symbol: RVX
CALGARY, Feb. 6, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) will be
hosting a conference call and webcast on Thursday, February 13, 2014 at
11 am MDT / 1 pm ET. The call will update the market on current
clinical and business structure options.
Details for the conference call and webcast are as follows:
Link to webcast: http://services.choruscall.ca/links/resverlogix140213.html
Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company
developing compounds involving ApoA-I production. RVX-208 is a
first-in-class small molecule in development for the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's
disease. RVX-208 is the first BET bromodomain inhibitor in clinical
trials. Resverlogix's common shares trade on the Toronto Stock Exchange
(TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).
| || || || || |
|Donald J. McCaffrey |
President and CEO
||Kenneth Lebioda |
SVP Business & Corporate Development
SOURCE Resverlogix Corp.